---
title: "Sera Prognostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 14 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285429104.md"
datetime: "2026-05-06T20:09:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285429104.md)
  - [en](https://longbridge.com/en/news/285429104.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285429104.md)
---

# Sera Prognostics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 14 K

Revenue: As of FY2026 Q1, the actual value is USD 14 K, missing the estimate of USD 66.67 K.

EPS: As of FY2026 Q1, the actual value is USD -0.17, missing the estimate of USD -0.1667.

#### Revenue

Revenue for the first quarter of 2026 was $14,000, a decrease compared to $38,000 for the first quarter of 2025.

#### Operating Expenses

Total operating expenses were $9.4 million for the first quarter of 2026, slightly up from $9.3 million for the same period in 2025.Research and development expenses were $3.0 million for the first quarter of 2026, down from $3.3 million in the first quarter of 2025.Selling, general and administrative expenses increased to $6.3 million for the first quarter of 2026, compared to $5.9 million for the prior-year period, reflecting investments in targeted commercial activities and market awareness.Cost of revenue was $42,000 for the first quarter of 2026, compared to $40,000 for the first quarter of 2025.

#### Net Loss

The net loss for the first quarter of 2026 was -$8.4 million, compared to -$8.2 million for the first quarter of 2025.Loss from operations was -$9.36 million for the first quarter of 2026, compared to -$9.25 million for the first quarter of 2025.

#### Cash and Securities

As of March 31, 2026, Sera Prognostics, Inc. held approximately $86.8 million in cash, cash equivalents, and available-for-sale securities.

#### Operational Metrics

Sera Prognostics, Inc. published the Landmark PRIME Randomized Trial, which demonstrated that the PreTRM® test reduced early preterm births (-56% <32 weeks; -32% <35 weeks), NICU admissions (-20%), and neonatal morbidity (-20%).The company expanded its European evidence base with two peer-reviewed publications, including the PREPARE Survey and expert commentary on the PRIME Trial.Commercial progress included launching a third partnership program expected to reach over 350 providers across three states, and engaging in active discussions with 13 payers across 15 states.Sera Prognostics, Inc. is advancing toward CE marking, with regulatory dossier preparation on track for mid-year submission.

#### Outlook / Guidance

Sera Prognostics, Inc. has extended its cash runway through 2029 by redirecting investment from clinical activities towards commercialization and rightsizing its operating model.This provides financial flexibility to fund the company through key adoption and commercial milestones, and the company anticipates future revenue expansion.

### Related Stocks

- [SERA.US](https://longbridge.com/en/quote/SERA.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [INTOUCH INSIGHT ANNOUNCES Q1 2026 FINANCIAL RESULTS](https://longbridge.com/en/news/287124506.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)